Key points to watch for in AstraZeneca’s upcoming earnings report

  • AstraZeneca’s Q4 revenue expected to be $12.01 billion, up from $11.21 billion in the same quarter last year
  • Core earnings per share expected to rise to $1.50 from $1.38 the year prior
  • Oncology therapy area, particularly lung cancer drug Tagrisso, expected to drive revenue growth
  • Cardiovascular, renal & metabolic portfolio expected to be led by diabetes drug Farxiga
  • Rare disease portfolio expected to improve with sales of Soliris and Ultomiris
  • AstraZeneca expected to guide for low-double digits percentage growth for earnings per share in 2024
  • Market interested in update on European biopharma sector’s thematics into 2024
  • AstraZeneca’s pipeline appreciation could significantly expand in the year ahead

AstraZeneca is set to report its fourth-quarter results, with expectations of increased revenue and core earnings per share. The company’s total revenue for the quarter is projected to be $12.01 billion, up from $11.21 billion in the same period last year. Core earnings per share are also expected to rise to $1.50 from $1.38. Investors will be watching to see if AstraZeneca’s actual figures meet or miss guidance. The company’s oncology therapy area, driven by its lung cancer drug Tagrisso, is expected to contribute to revenue growth. Additionally, the cardiovascular, renal & metabolic portfolio is anticipated to be led by the diabetes drug Farxiga, while the rare disease portfolio should see improvement from sales of Soliris and Ultomiris. Looking ahead, AstraZeneca is expected to guide for low-double digits percentage growth for earnings per share in 2024. The market will also be interested in updates on the European biopharma sector’s thematics into 2024, including M&A activity, obesity data, and drug pricing in the U.S. AstraZeneca’s pipeline appreciation is expected to expand in the coming year, with potential value in various cancers.

Public Companies: AstraZeneca (AZN)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 7
Justification: The article provides information about AstraZeneca’s expected revenue and earnings per share for the fourth quarter, based on analyst estimates. It also mentions the company’s guidance for 2023 and 2024, as well as potential revenue drivers and market trends. The information provided seems to be based on reliable sources and does not contain any obvious bias or misleading information. However, it is important to note that these are estimates and projections, and the actual results may differ.

Noise Level: 7
Justification: The article provides information on AstraZeneca’s expected revenue and earnings per share for the fourth quarter, as well as guidance for 2023 and 2024. It also mentions revenue drivers and market trends. However, the article lacks scientific rigor and intellectual honesty, as it does not provide any evidence or data to support its claims. It also does not provide actionable insights or solutions for the reader.

Financial Relevance: Yes
Financial Markets Impacted: The financial markets that may be impacted by AstraZeneca’s fourth-quarter results include the pharmaceutical industry and investors in AstraZeneca’s stock.

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article primarily focuses on AstraZeneca’s financial performance and future guidance, without mentioning any extreme events or their impact.

Reported publicly: www.marketwatch.com